We examined whether CB 1 receptors in smooth muscle conform to the signaling pattern observed with other G i-coupled receptors that stimulate contraction via two G␥-dependent pathways (PLC-3 and phosphatidylinositol 3-kinase/integrin-linked kinase). Here we show that the anticipated G␥-dependent signaling was abrogated. Except for inhibition of adenylyl cyclase via G␣ i, signaling resulted from G␥-independent phosphorylation of CB 1 receptors by GRK5, recruitment of -arrestin1/2, and activation of ERK1/2 and Src kinase. Neither uncoupling of CB1 receptors from Gi by pertussis toxin (PTx) or Gi minigene nor expression of a G␥-scavenging peptide had any effect on ERK1/2 activity. The latter was abolished in muscle cells expressing -arrestin1/2 siRNA. CB 1 receptor internalization and both ERK1/2 and Src kinase activities were abolished in cells expressing kinase-deficient GRK5(K215R). Activation of ERK1/2 and Src kinase endowed CB 1 receptors with the ability to inhibit concurrent contractile activity. We identified a consensus sequence ( 102 KSPSKLSP 109 ) for phosphorylation of RGS4 by ERK1/2 and showed that expression of a RGS4 mutant lacking Ser 103 /Ser 108 blocked the ability of anandamide to inhibit acetylcholine-mediated phosphoinositide hydrolysis or enhance G␣q:RGS4 association and inactivation of G␣q. Activation of Src kinase by anandamide enhanced both myosin phosphatase RhoA-interacting protein (M-RIP):RhoA and M-RIP:MYPT1 association and inhibited Rho kinase activity, leading to increase of myosin light chain (MLC) phosphatase activity and inhibition of sustained muscle contraction. Thus, unlike other Gi-coupled receptors in smooth muscle, CB1 receptors did not engage G␥ but signaled via GRK5/ -arrestin activation of ERK1/2 and Src kinase: ERK1/2 accelerated inactivation of G␣q by RGS4, and Src kinase enhanced MLC phosphatase activity, leading to inhibition of ACh-stimulated contraction. beta arrestin; CB1 receptors; ERK1/2; GRK5; Src kinase THE PROPERTIES AND ROLE OF G protein-coupled cannabinoid receptors, CB 1 and CB 2 , have been extensively studied in their primary locations: the central and peripheral nervous system and the immune system, respectively (3,8,22,32). The location of CB 1 receptors in the brain (cerebral cortex, hippocampus, basal ganglia, amygdala, and cerebellum) correlates with the observed psychotropic effects of cannabinoids. It is increasingly evident, however, that CB 1 receptors and the endocannabinoid system that provides them with lipid ligands on demand are more widely distributed, though less abundantly than in neural tissue. Thus CB 1 receptors are expressed in both vascular and visceral smooth muscle [e.g., cerebral arterial smooth muscle (7), vas deferens (5), and myometrial smooth muscle (2)], where they signal variously via G␣ i -dependent inhibition of adenylyl cyclase and G␥-dependent inhibition of voltage-gated L-type Ca 2ϩ channels, and activation of various kinases [phosphatidylinositol 3-kinase (PI 3-kinase), extracellular signal-regulated kinase (E...